Posting of Circular and Notice of General Meeting

RNS Number : 3892R

Destiny Pharma PLC

28 February 2023

 

28 February 2023

Destiny Pharma plc

Posting of Circular and Notice of General Meeting

Destiny Pharma plc (AIM: DEST) (the "Company" or "Destiny Pharma"), is pleased to confirm that, further to the announcement of 24 February 2023, the shareholder circular (the "Circular") providing further details of the Placing, Subscription and the Open Offer and notice of General Meeting has been posted to shareholders today.

The Circular contains a Notice of General Meeting to be held at the offices of Covington & Burling LLP, 22 Bishopsgate, London, EC2N 4BQ on 16 March 2023 at 2.00 p.m. (the "General Meeting").  Please note that the time of the General Meeting has changed from that announced on 24 February 2023.

A copy of the Circular, Open Offer Application Form and Form of Proxy will shortly be available from the Company's website (www.destinypharma.com).

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular.

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

			2023
Announcement of the Placing, the Open Offer and the Subscription		24 February
Record Date for entitlements under the Open Offer		Close of business on 23 February
Ex-entitlement Date for the Open Offer		8.00 a.m. on 27 February
Posting of the Circular (including the Notice of General Meeting), the Form of Proxy and, to Qualifying Non-CREST Shareholders, the Application Form		28 February
Basic Entitlements and Excess Entitlements credited to stock accounts of Qualifying CREST Shareholders		As soon as possible on 1 March
First Admission and commencement of dealings in the Placing Shares and the Subscription Shares on AIM		8.00 a.m. on 1 March
First Placing Shares in uncertificated form pursuant to First Admission expected to be credited to accounts in CREST		As soon as possible after 8.00 a.m. on 1 March
Recommended latest time and date for requesting withdrawal of Basic Entitlements and Excess Entitlements from CREST		4.30 p.m. on 9 March
Latest time and date for depositing Basic Entitlements and Excess Entitlements into CREST		3.00 p.m. on 10 March
Latest time and date for splitting Application Forms (to satisfy bona fide market claims only)		3.00 p.m. on 13 March
Latest time and date for receipt of completed Application Forms and payment in full under the Open Offer or settlement of relevant CREST instructions (as appropriate)		11.00 a.m. on 15 March
Announcement of the results of the Open Offer		15 March
Latest time and date for receipt of CREST proxy instructions and registration of online votes from Shareholders for General Meeting		2.00 p.m. on 14 March
Latest time and date for receipt of Forms of Proxy		2.00 p.m. on 14 March
General Meeting		2.00 p.m. on 16 March
Announcement of the results of the General Meeting		16 March
Second Admission and commencement of dealings in the Committed Open Offer Shares on AIM		8.00 a.m. on 17 March
Committed Open Offer Shares in uncertificated form pursuant to Second Admission expected to be credited to accounts in CREST (uncertificated holders only)		As soon as possible after 8.00 a.m. on 17 March
Dispatch of definitive share certificates for the New Shares in certificated form	Within 5 business days of First Admission, or Second Admission, where applicable

Each of the times and dates above refer to London time and are subject to change at the absolute discretion of the Company, finnCap and Shore Capital. Any such change will be notified to Shareholders by an announcement through a Regulatory Information Service. Certain of the events in the above timetable are conditional upon, inter alia, the approval of the Resolutions to be proposed at the General Meeting.

For further information, please contact: 

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

[phone] 

[e-mail]  

finnCap Ltd  (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

[phone]

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

Optimum Strategic Communications 

Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper

[phone]

[e-mail]  

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

Stern IR - US

Janhavi Mohite

[phone]

[e-mail]

 

END

 

 

NOGKZGZZKRDGFZM